Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.8 USD | 0.00% | +2.36% | +75.65% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
Financials (USD)
Sales 2024 * | 5.84M | Sales 2025 * | 4.43M | Capitalization | 1.52B |
---|---|---|---|---|---|
Net income 2024 * | -174M | Net income 2025 * | -193M | EV / Sales 2024 * | 151 x |
Net cash position 2024 * | 638M | Net cash position 2025 * | 333M | EV / Sales 2025 * | 269 x |
P/E ratio 2024 * |
-9.03
x | P/E ratio 2025 * |
-10.6
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.69% |
Latest transcript on Spyre Therapeutics, Inc.
1 week | +2.36% | ||
Current month | +14.44% | ||
1 month | +6.24% | ||
3 months | +62.79% | ||
6 months | +268.78% | ||
Current year | +75.65% |
Managers | Title | Age | Since |
---|---|---|---|
Cameron Turtle
CEO | Chief Executive Officer | 34 | 23-06-21 |
Scott Burrows
DFI | Director of Finance/CFO | 47 | 23-08-31 |
Brian Connolly
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 26 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tomas Kiselak
BRD | Director/Board Member | 38 | 23-06-21 |
Jeffrey Albers
BRD | Director/Board Member | 52 | Nov. 26 |
Peter Harwin
BRD | Director/Board Member | 38 | 23-06-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 37.8 | 0.00% | 308,277 |
24-05-16 | 37.8 | +1.12% | 282,967 |
24-05-15 | 37.38 | -4.86% | 299,261 |
24-05-14 | 39.29 | +6.19% | 400,122 |
24-05-13 | 37 | +0.19% | 274,679 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.65% | 1.52B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- SYRE Stock